

## Orasure Technologies to Present at the 39th Annual Canaccord Genuity Growth Conference

July 31, 2019

BETHLEHEM, Pa., July 31, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the 39<sup>th</sup> Annual Canaccord Genuity Growth Conference. The conference will be simultaneously webcast over the Internet.

Dr. Tang is scheduled to speak on Wednesday, August 7, 2019, at approximately 8:00 AM Eastern Time (5:00 AM Pacific Time). Interested investors can access the live webcast of the presentation by going to OraSure Technologies' web site, <u>www.orasure.com</u> and clicking on the Investors link. A replay of the webcast will be available on OraSure Technologies' web site for seven days. Alternatively, you can access the live webcast of the presentation via the following link: <u>http://wsw.com/webcast/canaccord35/osur/</u>

## **About OraSure Technologies**

OraSure Technologies is empowering the global community to improve health and wellness by providing access to accurate essential information. OraSure is a leader in the development, manufacture and distribution of point-of-care diagnostic tests, molecular collection devices and other technologies designed to detect or diagnose critical medical conditions. Its first-to-market, innovative products include rapid tests for the detection of antibodies to HIV and Hepatitis C (HCV) on the OraQuick<sup>®</sup> platform, sample self-collection and stabilization products for molecular applications, and oral fluid laboratory tests for detecting various drugs of abuse. Together with its wholly-owned subsidiaries (DNA Genotek, CoreBiome and Novosanis), OraSure provides its customers with value-added, end-to-end solutions that encompass tools, diagnostics and services. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research institutions, distributors, government agencies, physicians' offices, commercial and industrial entities and consumers. For more information on OraSure Technologies, please visit <u>www.orasure.com</u>.

Company contact:

Roberto Cuca Chief Financial Officer 610-882-1820 Investorinfo@orasure.com www.orasure.com Jeanne Mell VP Corporate Communications 484-353-1575 <u>media@orasure.com</u> www.orasure.com



Source: OraSure Technologies, Inc.